Key Developments: Lonza Group AG (LONN.VX)
Latest Key Developments (Source: Significant Developments)
Lonza Group AG announced that it will distribute a dividend of CHF 2.15 per share for the fiscal year 2012. Full Article
Sartorius Stedim Biotech SA Expands Product Portfolio in Cell Culture Range via Cooperation with Lonza Group AG
Sartorius Stedim Biotech SA (SSB) announced an expansion of its product array in the cell culture range as it signed a cooperation agreement with Lonza Group AG on long-term, global collaboration in the field of cell culture media. The cooperation agreement provides that SSB will assume global sales and marketing of Lonza's media and buffers used in the manufacture of protein-based therapeutics and vaccines, while Lonza will continue to carry out development, manufacture and logistics operations for these products. New product development will be mutually performed. The cell culture media, which are usually sold in liquid or powder form to biopharmaceutical customers, are to be successively converted to packaged forms as ready-to-use, prefilled SSB sterile single-use bags. Furthermore, Lonza and SSB have agreed that these cell culture media will be sold under both brands in a co-branding arrangement. Full Article
Reuters reported that Lonza Group AG plans to cut 500 jobs, including 400 at its main plant in southern Switzerland, as it grapples with low-cost competition. The cuts at the Basel-based firm equate to around 5% of its global workforce of about 11,000. The group said on Wednesday it would cut 400 jobs at Visp, southern Switzerland, and 100 management positions around the world over the next year. Full Article
Lonza Group AG announced at a meeting on April 2, 2012, the Board of Directors of Lonza elected Mr. Richard Ridinger as the new Chief Executive Officer (CEO) of Lonza. Mr. Ridinger will become CEO of Lonza effective May 1, 2012. Rolf Soiron was acting CEO as interim, since the end of January. Full Article
Lonza Group AG (Lonza) announced a global commercial partnership with Lipogen for the exclusive rights to sell phosphatidylserine (PS) and PS-based formulations in dietary supplements, medical foods, and food and beverages under the Lonza name. Lonza intends to roll out launch activities in the United States in the fourth quarter of fiscal year 2011, and expand to other global regions thereafter. Full Article
Lonza Group AG Receives Antitrust Clearance in France for Its Tender Offer through LG Acquisition Corp for Purchase of Arch Chemicals, Inc.
Lonza Group AG announced that it has obtained antitrust clearance from the Autorite de la Concurrence in France for its tender offer, through its wholly owned subsidiary LG Acquisition Corp, for 100% of the outstanding shares of common stock of Arch Chemicals, Inc. Full Article
Mesoblast Ltd announced that the Company and Lonza Group (SWS: LONN have entered into a strategic alliance for clinical and long-term commercial production of Mesoblast’s off-the-shelf (allogeneic) adult stem cell products. Under the agreement: Lonza will supply Mesoblast’s clinical and long-term commercial MPC product needs globally; Mesoblast can trigger a process requiring Lonza to construct a purpose-built manufacturing facility exclusively for Mesoblast’s marketed products. In return, Mesoblast will purchase agreed quantities of marketed products from the facility; Mesoblast can exercise its right to buy out this manufacturing facility at a pre-agreed purchase price two years after the facility receives regulatory approval; Mesoblast will have exclusive access to Lonza's Cell Therapy facilities in Singapore for the manufacture of allogeneic cell therapy products, subject to certain exceptions; and Lonza will utilize its intellectual property to facilitate reductions in Mesoblast's manufacturing costs and help enable development of enhanced second generation products. Full Article
Genesis Biopharma Inc and Lonza Group AG announced the signing of a process development and scale-up agreement relating to the manufacture of Contego, Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma. Contego is a ready-to-infuse cell therapy based on currently available therapies at the National Cancer Institute, MD Anderson Cancer Center, and the H. Lee Moffitt Cancer & Research Institute. Full Article
Lonza Group AG announced an exclusive contract for the production of IMMUNE Pharmaceutical's human immunoglobulin monoclonal antibody, Bertilimumab, under investigation for the potential treatment of several inflammatory disorders. Under the agreement, Lonza will produce phase 2 clinical trial material at its mammalian development and manufacturing facility. Bertilimumab has great potential for the treatment of eosinophilic inflammatory bowel diseases (IBD) - Crohn’s Disease and Ulcerative Colitis - and eosinophilic gastro-intestinal diseases (EGID). Bertilimumab is the first monoclonal antibody to specifically neutralize human eotaxin-1, a chemokine associated with inflammatory disease activity. Financial details were not disclosed. Full Article
Lonza Group AG's Subsidiary Commences Tender Offer To Acquire All Of Outstanding Shares Of Arch Chemicals, Inc.
Lonza Group AG announced that an indirect wholly owned subsidiary of Lonza, LG Acquisition Corp., has commenced the previously announced offer to acquire all of the outstanding shares of common stock of Arch Chemicals, Inc. at a price of USD47.20 per share, net to the seller in cash, without interest and less any required withholding of taxes. Lonza and Arch Chemicals announced on July 11, 2011 the signing of a definitive merger agreement pursuant to which the tender offer would be made. The board of directors of Arch Chemicals has unanimously approved the terms of the merger agreement and recommended that Arch Chemicals shareholders tender their shares pursuant to the tender offer. The tender offer is scheduled to expire on August 11, 2011, unless the tender offer is extended or earlier terminated in accordance with the terms of the merger agreement and the applicable rules and regulations of the SEC. Full Article
ZURICH, April 24 - Speciality chemicals and life sciences group Lonza plans to close a plant in Ireland as part of an overhaul aimed at boosting profitability, the company said as it confirmed its earnings target for 2013.